NZM2.DU NOVOZYMES -B-
- Market cap
- -
- P/E
- 44.8x
- P/B
- 2.56x
- ROE
- 6.6%
- Dividend yield
- -
- Fundamental score
- 2.7/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is NZM2.DU undervalued?
Graham numberThe Graham number of NOVOZYMES -B- cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NOVOZYMES -B- fundamental analysis
12 of 22 checks passedROE 0/2
Low return on equity (6.6%), below 10%.
ROA 1/1
Return on assets (4.5%) is above the industry median (3.8%).
Profit Consistency 2/2
Profitable for 10 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 1/1
Last year's EPS growth (90.9%) is above the 5-year average (-34.1% a year).
Earnings Growth vs Industry 1/1
Last year's EPS growth (90.9%) is above the industry median (7.9%).
Revenue Growth 2/2
Revenue grew 20.8% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 0/1
Current assets do not cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (25.4%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
No interest expense reported.
PE vs Market 0/1
PE (44.8x) is above the market median (18.2x).
PE vs Industry 0/1
PE (44.8x) is above the industry median (18.3x).
PBV 0/1
Price to book (2.6x) is above the industry median (2.0x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 114.8, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 1/2
Dividend yield (2.1%) is above the bottom 25% of dividend payers in the market.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 1/1
Payout ratio is 69.0%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
NOVOZYMES -B- stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
NOVOZYMES -B- financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
NOVOZYMES -B- annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 14.1B | 14.5B | 14.4B | 14.4B | 14.0B | 2.01B | 2.36B | 2.40B | 3.83B | 4.16B | 4.47B |
| Gross Profit | 8.13B | 8.41B | 8.26B | 7.95B | 7.85B | 1.16B | 1.29B | 1.30B | 1.81B | 2.24B | 2.51B |
| Operating Income | 3.95B | 4.11B | 4.07B | 3.55B | 3.61B | 522M | 594M | 611M | 659M | 883M | 1.07B |
| EBITDA | - | 4.94B | 4.96B | 5.07B | 4.85B | 5.44B | 821M | 734M | 1.04B | 1.39B | 1.07B |
| Net Income | 3.05B | 3.12B | 3.23B | 3.15B | 2.83B | 423M | 493M | 406M | 306M | 584M | 742M |
| EPS | - | 11 | 11 | 11 | 10 | 1.53 | 1.78 | 1.46 | 0.66 | 1.25 | 1.59 |
| Balance Sheet | |||||||||||
| Total Assets | 18.7B | 18.4B | 19.7B | 20.4B | 20.5B | 3.33B | 3.76B | 3.81B | 15.2B | 16.3B | 16.6B |
| Total Liabilities | 6.91B | 7.11B | 8.26B | 8.96B | 9.27B | 1.69B | 1.85B | 1.88B | 4.02B | 5.49B | 5.48B |
| Shareholders' Equity | 11.7B | 11.3B | 11.4B | 11.5B | 11.2B | 1.59B | 1.86B | 1.88B | 11.2B | 10.9B | 11.2B |
| Cash & Short-term Investments | 812M | 632M | 723M | 711M | 1.18B | 129M | 140M | 150M | 280M | 275M | 309M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 3.84B | 4.06B | 3.68B | 3.20B | 4.36B | 4.06B | 4.01B | 557M | 1.02B | 1.22B | 1.05B |
| Capital Expenditure | 1.22B | 1.69B | 1.39B | 997M | 940M | 1.24B | 2.89B | 276M | 360M | 471M | 432M |
| Free Cash Flow | - | 2.37B | 2.29B | 2.20B | 3.42B | 2.82B | 1.12B | 281M | 660M | 751M | 614M |
| Ratios | |||||||||||
| ROE | 26.0% | 27.7% | 28.2% | 27.5% | 25.1% | 26.6% | 26.6% | 21.6% | 2.7% | 5.4% | 6.6% |
| ROA | 16.3% | 17.0% | 16.4% | 15.4% | 13.8% | 12.7% | 13.1% | 10.7% | 2.0% | 3.6% | 4.5% |
| Net Profit Margin | 21.6% | 21.5% | 22.4% | 21.9% | 20.2% | 21.0% | 20.9% | 16.9% | 8.0% | 14.0% | 16.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
NOVOZYMES -B- dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- 69.0%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 403M | 0.86 | 69.0% |
| 2024 | EUR 250M | 0.54 | 81.7% |
| 2023 | EUR 383M | 1.38 | 94.4% |
| 2022 | DKK 1.53B | 5.51 | 309.1% |
| 2021 | DKK 1.47B | 5.29 | 346.6% |
| 2020 | DKK 1.48B | 5.31 | 52.5% |
| 2019 | DKK 1.44B | 5.11 | 45.6% |
| 2018 | DKK 1.32B | 4.58 | 40.8% |
| 2017 | DKK 1.19B | 4.07 | 38.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 5:1 on Nov 28, 2011.
Who owns NOVOZYMES -B-
Ownership data of NOVOZYMES -B- is not available yet.
NOVOZYMES -B- company profile
- Company name
- NOVOZYMES -B-
- Ticker
- NZM2.DU
- Exchange
- Dusseldorf Exchange
- Sector
- Other
- Industry
- Metals & Mining
- Fiscal year end
- December
- Address
- Website
- -
About NOVOZYMES -B-
There is no Profile data available for NZM2.DU.